Furthermore, miR‐126 inhibition reversed the dysplastic phenotype observed in the NHD13+ mouse, a murine MDS model, and decreased engraftment of primary human MDS CD34+ cells in immunodeficient mice. This evidence concerns the gene CD34 and myelodysplastic syndrome.